Received Date: Oct 08, 2018 / Accepted Date: Oct 12, 2018 / Published Date: Oct 19, 2018

Keywords: Alzheimer’s; Mild cognitive impairment; Programmatics; ReCODE; Precision medicine; Amyloid precursor protein; Synaptoblastic; Synaptoclastic

Introduction

Alzheimer’s disease is now the third leading cause of death in the United States [1-6], and the development of effective treatment and prevention is a major healthcare goal. However, clinical trials of drug candidates for Alzheimer’s disease treatment have been almost uniformly unsuccessful. There may be several reasons for such repeated failure: (1) given the long pre-symptomatic period, treatment is typically initiated late in the pathophysiological process; (2) what is referred to as Alzheimer’s disease is not a single disease, but rather exhibits several different subtypes [3,4]; (3) just as for other complex chronic illnesses such as cardiovascular disease, there may be many potential contributors to Alzheimer’s disease, such as inflammation, various chronic pathogens, trophic withdrawal, insulin resistance, vascular compromise, trauma, and exposure to specific toxins. Therefore, a monotherapeutic, monophasic approach is likely to be suboptimal, and personalized, multiphasic programs based on each individual’s genetics and biochemistry may be preferable. Indeed, such personalized programs may offer advantages in future clinical trials of drug candidates. (4) The model of Alzheimer’s disease on which the drug targets (e.g., amyloid-β peptide) have been based may be an inaccurate or incomplete model of the disease. model is compatible with the finding that the Aβ peptide functions as an antimicrobial peptide [11], together suggesting that what is referred to as Alzheimer’s disease is a protective, network-downsizing response to several classes of insults: pathogens/inflammation, toxins, and withdrawal of nutrients, hormones, or trophic factors [5]. We have argued for a fundamentally different view of Alzheimer’s disease [1,2,5,7] in which APP, the amyloid precursor protein, functions as a molecular switch due to its activity as an integrating dependence receptor [8-10]: in the presence of sufficient support from trophic signaling, APP is cleaved at the alpha site, leading to the production of two synaptoblastic peptides, sAPPα and αCTF. In contrast, in the absence of sufficient support from trophic signaling, APP is cleaved at the beta, gamma, and caspase sites, leading to the production of four synaptoclastic peptides, sAPPβ, Aβ, Jcasp, and C31. In this model, inflammation exerts an anti-trophic effect on APP signaling, at least in part via the NF-κB (nuclear factor κ-light chain enhancer of B cells) induction of BACE (beta-amyloid cleaving enzyme) and gamma-secretase activity. Similarly, toxins such as divalent metals (e.g., mercury) also exert an anti-trophic effect on APP signaling, since these lead to a net increased production of the toxin-binding peptide, Aβ. This model is compatible with the finding that the Aβ peptide functions as an antimicrobial peptide [11], together suggesting that what is referred to as Alzheimer’s disease is a protective, network-downsizing response to several classes of insults: pathogens/inflammation, toxins, and withdrawal of nutrients, hormones, or trophic factors [5]. This model suggests that the probability of developing Alzheimer’s disease is proportional to the ratio of synaptoclastic signaling to synaptoblastic signaling [5]. This notion has led to a treatment regimen in which the dozens of contributors to synaptoblastic and synaptoclastic signaling are measured for each patient, and a personalized program is generated to target each contributor, thus increasing synaptoblastic signals and reducing identified synaptoclastic signals. Some examples include: (1) identifying and treating pathogens such as Borrelia, Babesia, or Herpes family viruses; (2) identifying gastrointestinal hyperpermeability, repairing the gut, and enhancing the microbiome; (3) identifying insulin resistance and protein glycation, and returning insulin sensitivity and reduced protein glycation; (4) identifying and correcting suboptimal nutrient, hormone, or trophic support (including vascular support); (5) identifying toxins (metallotoxins and other inorganics, organic toxins, or biotoxins), reducing toxin exposure, and detoxifying. Since each patient has a different combination of the many potential contributors to cognitive decline, the approach to treatment is targeted and personalized. Here we describe 100 patients with cognitive decline treated with this multi-component, precision medicine approach, and showing documented improvement.

Case Studies

Patient 1 A 68-year-old professional woman began to note paraphasic errors in her speech, severe enough that it created confusion in her listeners. She also developed depression, and was treated with an antidepressant. She began to have difficulty with everyday work such as shopping, cooking, and working at the computer. She struggled to complete a gingerbread man with her granddaughter, even though she had done this without difficulty many times before. She confused the minute hand and hour hand on a clock. She had difficulty with spelling. Her symptoms progressed, and she began to forget daily tasks. She became very concerned when she forgot to pick up her grandchildren at school twice in a two-week period. She was found to be heterozygous for the ε4 allele of apolipoprotein E (ApoE 3/4). An amyloid PET scan (florbetapir) was positive. MRI demonstrated a hippocampal volume of 14th percentile for her age. High-sensitivity C-reactive protein (hs-CRP) was 1.1 mg/L, fasting insulin 5.6 mIU/L, hemoglobin A1c 5.5%, homocysteine 8.4 micromolar, vitamin B12 471 pg/mL, free triiodothyronine (free T3) 2.57 pg/mL, thyroid-stimulating hormone (TSH) 0.21 mIU/L, albumin 3.7 g/dL, globulin 2.7 g/dL, total cholesterol 130 mg/dL, triglycerides 29 mg/dL, serum zinc 49 mcg/dL, complement factor 4a (C4a) 7990 ng/mL, transforming growth factor beta-1 (TGF-β1) 4460 pg/ml, and matrix metalloprotease-9 497 ng/mL. A diagnosis of Mild Cognitive Impairment (MCI) was made, and she was placed on a trial of an anti-amyloid antibody. However, with each administration, her cognition became worse for 3-5 days, then returned toward her previous MCI status. After she had become worse with each of the first four treatments, she discontinued her participation in the study. She began treatment with the programmatic approach described previously [1]. Her MoCA increased from 24 to 30 over 17 months, and has remained stable for 18 months. Hippocampal volume increased from 14th percentile to 28th. Her symptoms improved markedly: her ability to spell returned, her speech improved, and her ability to shop, cook, and work at the computer all improved and have remained stable on follow-up. Patient 2 A 73-year-old female physician presented with a history of memory decline and word-finding problems that had begun insidiously nearly 20 years previously, but had accelerated over the past year, leading her significant other to describe her memory as “disastrous.” She could not remember recent conversations, plays she had seen, or books she had read, and mixed up the names of people and pets. She had trouble navigating, even difficulty finding her way back to her restaurant table after using the restroom. Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) scan revealed a decrease in glucose utilization in the anterior superior precuneus bilaterally, as well as the anterolateral left temporal lobe. MRI revealed mild biparietal atrophy, with decreased hippocampal volume (16th percentile for age). On-line cognitive testing placed her at the 9th percentile for her age. ApoE genotype was 3/3, fasting glucose 90 mg/dL, hemoglobin A1c 5.3%, fasting insulin 1.6 mIU/L, homocysteine 14.1 micromolar, TSH 4.1 mIU/mL, free T3 2.6 pg/mL, reverse T3 22.6 ng/dL, vitamin B12 202 pg/mL, vitamin D 27.4 ng/mL, total cholesterol 226 mg/dL, LDL 121 mg/dL, HDL 92 mg/dL, and mercury 7 ng/mL. She was treated with the programmatic approach described previously [1], and over 12 months, her on-line cognitive assessment improved from the 9th percentile to the 97th percentile. Her significant other noted that her memory had improved from “disastrous” to “just plain lousy” and finally to “normal.” She remains on the therapeutic program, and has sustained her improvement. Patient 3 A 62-year-old woman presented with cognitive decline, fatigue, poor sleep, and depression. She had lost the ability to remember names, do the accounting she had done previously, and run her business. Body mass index was 24, with increased abdominal fat. MoCA was 20. She was ApoE4 heterozygous (3/4). Fasting serum glucose 101 mg/dL, hemoglobin A1c 6.1%, fasting insulin 14 mIU/L, hs-CRP 1.7 mg/L, 25-hydroxycholecalciferol 24 ng/mL, TSH 2.4 mIU/L, free T3 2.9 pg/mL, reverse T3 19 ng/dL, estradiol<6 pg/mL, and pregnenolone 38 ng/dL. Pathogen testing was negative for Borrelia, other tick-borne infections, and Herpes family viruses. Toxin testing showed no evidence of mercury or lead toxicity. She was treated with the personalized program described previously [1], which in her case included bio-identical hormone replacement, restoring insulin sensitivity with a mildly ketogenic, plant-rich diet, regular exercise, and stress reduction; enhancing her microbiome with probiotics and prebiotics; reducing systemic inflammation with omega-3 fats; enhancing vitamin D and vitamin K2; enhancing methylation with methyl-cobalamin and methyl-tetrahydrofolate; and brain training. Over the next 12 months she improved her metabolic status: her BMI dropped to 21.8, fasting glucose 87 mg/dL, hemoglobin A1c 5.2%, fasting insulin 5.5 mIU/L, hs-CRP 0.5 mg/L, free T3 3.2 pg/mL, TSH 2.1 mIU/L, estradiol 51 pg/mL. Her symptoms resolved, she was able to reopen her business, and her follow-up MoCA score had risen from 20 to 28. Her improvement has been sustained. (Table 1) lists 100 patients with cognitive decline due to Alzheimer’s disease, pre-Alzheimer’s conditions MCI (Mild Cognitive Impairment) or SCI (Subjective Cognitive Impairment), or cognitive decline without definitive diagnosis, all of whom demonstrated documented improvement using the same targeted, multi-component program used for the three patients described above. Patient ApoE Sx Dx Evaluation F/u Comment 1) 68F 3/4 Exec, calc MCI Am-PET+ MoCA 24→30 Patient 1 (above) 2) 73F 3/3 Amnestic MCI FDG-PET+ 9→97%ile on-line Patient 2 (above) 3) 59F 3/4 Exec AD HC vol <1%ile MoCA 14→21 4) 62F ND Multi-domain AD MoCA 9→17 Returned to work 5) 75F 3/4 Multi-domain MCI CSF ATI+ MoCA 21→25; MSQ 47→6 6) 65M 3/4 Multi-domain AD CSF ATI+ MoCA 8→12; MSQ 45→20 7) 69M ND Amnestic, VS, calc AD MRI, CSF ATI+ MoCA 19→26 8) 57M ND Amnestic, exec, VS AD CSF ATI+ MoCA 15→27 9) 68F ND Amnestic, exec MCI MRI MoCA 26→27; MSQ 34→18 Marked functional improvement 10) 85M 3/3 Amnestic, VS MCI HC vol 9%ile MoCA 20→21; MSQ 11→7 11) 86M ND Amnestic, exec, VS MCI CSF ATI+ MoCA 22→24 12) 60M 3/4 Amnestic, exec, VS AD MRI, NP MoCA 17→21; MSQ 43→25 Improved QOL 13) 64F ND Amnestic, exec, VS AD MRI MoCA 20→24; MSQ 40→10 14) 77M ND Amnestic, VS, calc MCI MRI MoCA 24→28; MSQ 91→42 15) 64M ND Amnestic, exec, calc, VS AD FDG-PET+ MoCA 13→19 16) 50M 3/3 Amnestic, aphasic SCI MRI MoCA 27→28; MSQ 88→57 17) 70M ND Amnestic, exec, aphasic, VS AD FDG-PET+ MoCa 19→24; MSQ 16→4 Marked subjective improvement; cont’d high-level employment 18) 80M 3/4 Amnestic, exec, VS MCI CSF ATI+ MoCA 19→20 19) 57M ND Severe multi-domain AD MRI, NP, CSF MoCA 0→5; MSQ 36→16 20) 80M 3/3 Amnestic SCI MoCA 26→29; MSQ 25→4 21) 69M ND Amnestic MCI MoCA 26→30; MSQ 31→20 22) 56F 4/4 Amnestic, exec, VS AD FDG-PET+ MoCA 5→8; MSQ 14→8 23) 69M ND Amnestic AD MRI MoCA 19→26; MSQ 29→17 Doing well at work 24) 83F 3/4 Amnestic MCI MRI MoCA 23→27; MSQ 31→20 25) 71F 3/3 Amnestic, exec AD qEEG MoCA 18→23; CNS-VS exec 1→63%ile; cog flex 1→58%ile; qEEG 2SD increase beta power Marked memory improvement; return to driving and independence 26) 75M ND Exec MCI qEEG MoCA 21→29; qEEG normalized 27) 67F 3/4 Amnestic, exec AD qEEG MoCA 15→19 Insomnia resolved 28) 61F ND Amnestic, exec SCI qEEG CNS-VS NCI 40→73%ile; qEEG global beta power normalized Marked subjective improvement 29) 61F 2/4 Exec MCI qEEG CNS-VS 4→68%ile Able to DC stimulant medication 30) 71M 3/3 Amnestic, exec SCI qEEG CNS-VS 30→81%ile 31) 63F 4/4 Amnestic, exec AD qEEG MoCA 3→4 Decline halted 32) 78M 3/3 Amnestic, exec AD qEEG MoCA 9→13 Marked subjective improvement, regained dressing and independent bathroom use 33) 50M 3/4 Amnestic, exec, calc AD Am-PET+, FDG-PET+ MoCA 0→9 Marked subjective improvement 34) 71M 2/3 Amnestic MCI MoCA 24→29 35) 81F 3/4 Amnestic AD HC atrophy MoCA 10→12 Marked subjective improvement 36) 78M 4/4 Amnestic AD HC volume <1%ile MoCA 16→20 Able to run his business 37) 77M 3/4 Amnestic AD FDG-PET+ MoCA 14→18 Clear subjective improvement 38) 85F 3/4 Amnestic AD MoCA 21→24, stable 1.5y+ Word recall markedly improved 39) 70M ND Amnestic AD FDG-PET+, CSF ATI+ MoCA 19→27; MSQ 16→7 40) 54F ND Amnestic AD MoCA 19→23; MSQ 84→41 41) 70F 3/3 Amnestic SCI CVLT 39→59%ile 42) 79M 3/4 Amnestic AD SLUMS 14→18 43) 85M 3/4 Amnestic, exec AD SLUMS 17→22 44) 84M 3/3 Amnestic, exec MCI MRI SLUMS 19→26 45) 79F 3/3 Amnestic AD MoCA 14→18 46) 65M 4/4 Amnestic, exec MCI MRI, PET SLUMS 21→28 47) 68F 3/3 Amnestic MCI CVLT 18→26%ile 48) 54M 4/4 Amnestic SCI CVLT 54→62%ile 49) 77F 4/4 Amnestic MCI MRI MoCA 23→25; MSQ 17→7 50) 64M 3/3 AD SLUMS 15→20 51) 58F 3/3 Amnestic, exec AD CT: Cerebral atrophy CNS-VS memory

1→27%ile Marked subjective improvement 52) 70M 3/4 Amnestic AD MoCA 18→21 53) 62M 3/4 Amnestic, calc MCI MRI NP on-line 36→53%ile Marked subjective improvement 54) 58F 3/3 Exec, calc MCI NP CNS-VS 23→55%ile 55) 77M 3/4 Amnestic AD CT: cerebral atrophy CNS-VS 33→55%ile 56) 66F 4/4 Amnestic AD Cerebral atrophy CNS-VS 1→14%ile Returned independence 57) 72M 4/4 Amnestic MCI HC vol <5%ile CNS-VS 7→12%ile 58) 77M 3/4 Amnestic MCI MoCA 23→25 59) 83M 3/3 Amnestic AD Am-PET+ MMSE 24→28 60) 64M 4/4 Amnestic AD HC atrophy MMSE 22→29 61) 71M 3/4 Aphasic, exec AD MRI MoCA 5→ Declined Vastly improved, conversing again, dressing himself, calling grandchildren by name, working again 62) 73F 3/4 Amnestic AD qEEG, evoked potentials MoCA 9→20; AQ21 20→8; P300b lat. 608→576; P300b amp. 13→15.6 63) 62F ND Amnestic MCI/

AD MoCA 20→28 Patient 3 (above) 64) 73M 4/4 Amnestic MCI MoCA 25→30 65) 69F 3/4 Amnestic, exec AD MoCA 16→19 Minimal speech→fluid normal speech 66) 58M 3/4 Amnestic MCI MRI; HC vol 12%ile MoCA 26→28; HC vol 12→24%ile Rapid decline prior to treatment 67) 70F 3/3 Amnestic MCI CNS-VS NCI 32→61%ile; psych speed 3→68%ile 68) 91M ND Exec AD MMSE 22→27 69) 76F 3/4 Amnestic, exec AD MRI; HC vol 47%ile MoCA 17→25 Returned ability to read 70) 69M 3/3 Amnestic, calc AD Am-PET+ MoCA 15→25 71) 80M 3/4 Amnestic AD FDG-PET+ Memory score 15% Able to DC anti-hyp., statin; glucose improved 72) 64M 4/4 Amnestic, exec AD MRI: HC vol 10%ile, gen. atrophy MoCA 20→24 73) 75M 3/4 Amnestic, exec, VS AD MRI: HC vol 12%ile MoCA 6→9 Declined off protocol, improved back on 74) 62M ND Amnestic, exec AD MMSE 20→24 Improved writing and map following 75) 76M 3/3 Amnestic AD MRI MoCA 20→22 Improved memory 76) 50M 3/3 Exec AD FDG-PET+ MMSE 23→27 Marked subjective improvement 77) 53F 3/3 Exec, calc AD Am-PET+ MoCA 10→16 78) 50F 2/4 Amnestic MCI NP NP normalized, prosop. cleared, word finding improved Regained ability to play piano; sustained improvement 3y ongoing; f/u of pt. reported previously [4] 79) 68F 2/4 Amnestic, exec MCI MoCA 25→29 Memory, driving directions much improved 80) 80F 3/3 Amnestic, exec AD MoCA 18→24 Memory much improved 81) 61F 3/3 Exec AD FDG-PET: temp hypometab NCI 33→79%ile; exec 1→77%ile; cog flex 1→77%ile Marked subjective improvement 82) 54F 3/3 Amnestic, exec AD FDG-PET+ MoCA 19→21 Reading, navigating again; earlier f/u reported [4] 83) 78F 3/4 Amnestic, exec, praxis AD MRI: HC vol <1%ile MoCA 0→3 Striking change: speaking, dressing, dancing, biking, emailing, kayaking all returned 84) 74M 3/4 Amnestic AD FDG-PET+ CVLT-IIB 3→84%ile Improvement sustained at 4.5 yr; f/u to initial report [4] 85) 69F 3/4 Exec AD MRI: cerebral atrophy MoCA 18→27 Driver’s license returned; follows recipes again; nurse asked, “What happened?!” 86) 68M 3/4 Amnestic MCI Am-PET+; FDG-PET+ HC vol 17→75%ile Sustained improvement 4 yr; f/u to initial report [4] 87) 56M 3/3 Amnestic, exec, calc MCI FDG-PET+ Improved math, memory, able to play poker at high level again 88) 54F 4/4 Amnestic MCI NP: cog assessment 35→98%ile Sustained improvement 6 yr; f/u to [4] 89) 57F 4/4 Amnestic MCI NP NCI 16→73%ile Sustained improvement 2y; f/u to [4] 90) 76M 4/4 Amnestic AD FDG-PET+ MMSE 23→30 Declined when DC’d protocol, improved back on; f/u to [4] 91) 56F 4/4 Amnestic, exec, word finding MCI Composite memory 32→61%ile F/u to [4] 92) 48F 3/4 Amnestic MCI MoCA 23→30 Marked symptomatic improvement 93) 72M ND Amnestic, behavioral AD Improved memory, writing, reduced anxiety 94) 73F 3/4 Exec MCI MoCA 23→27 95) 70M 3/4 Amnestic, VS MCI Am-PET+ NP 30→50%ile Improved memory, navigation 96) 67F 4/4 Amnestic, exec, calc, behavioral AD SAGE 0 Return of addition, subtraction, multiplication, division; holding conversations again 97) 63M 3/4 Amnestic, exec, calc AD MRI: gray matter atrophy MoCA 17→29 Able to return to work 98) 74F 4/4 Amnestic, exec AD MRI: HC vol 18%ile, cortical atrophy MoCA 14→21 99) 79M 3/3 Amnestic AD MRI MoCA 11→15; MSQ 47→34 100) 78M 4/4 Amnestic AD MRI MoCA 20→23; MSQ 40→10 AD: Alzheimer’s Disease; Am-PET: Amyloid Positron Emission Tomography Scan; Anti-hyp: Antihypertensive; ApoE: Apolipoprotein E; ATI: Beta-Amyloid-Tau Index; Calc: Dyscalculia; CNS-VS: CNS Vital Signs; Cog: Cognitive; CSF: Cerebrospinal Fluid; CVLT: California Verbal Learning Test; DC: Discontinue; Dx: Diagnosis; Exec: Executive Function; F: Female; F/u: Follow-up; FDG-PET: Fluorodeoxyglucose Positron Emission Tomography Scan; Flex: Flexibility; HC vol: Hippocampal Volume; Hypometab: Hypometabolism; M: Male; MCI: Mild Cognitive Impairment; MMSE: Mini-Mental Status Exam; MoCA: Montreal Cognitive Assessment; MRI: Magnetic Resonance Imaging; MSQ: Mental Symptoms Questionnaire (score 0-284, higher=more symptomatic); NCI: Neurocognitive Index; ND: Not Done; NP: Neuropsychology; Prosop: Prosopagnosia; Psych: Psychomotor; Pt: Patient; qEEG: Quantitative Electroencephalogram; QOL: Quality of Life; SAGE: Self-Administered Gerocognitive Exam; SCI: Subjective Cognitive Impairment; SD: Standard Deviation(s); SLUMS: St. Louis University Mental Status Exam; Sx: Symptoms; Temp: Temporal; VS: Visuospatial Dysfunction. Table 1: Summary of 100 patients treated with a multi-factorial, precision medicine approach to cognitive decline [1,2] and showing improvement.

Discussion

Alzheimer’s disease represents a major healthcare problem, and the failure to develop effective treatment and prevention for Alzheimer’s would have dire consequences nationally and globally, the bankruptcy of Medicare being among them. Therefore, the development of effective treatments is a high priority for translational biomedicine and public health programs throughout the world. However, the area of neurodegenerative diseases is arguably the area of greatest biomedical therapeutic failure from Alzheimer’s to Parkinson’s to Lewy body disease to amyotrophic lateral sclerosis to frontotemporal dementia to progressive supranuclear paralysis to macular degeneration and other neurodegenerative diseases, there has been no effective treatment with a sustainable, disease-modifying effect. There may be several reasons for such uniform failure: attempting to treat without identifying the cause(s) and contributors for each patient may be one reason. Assuming a single cause, attempting to treat with a monotherapy, uniform and monophasic, may all contribute to previous suboptimal and ineffective approaches. Furthermore, targeting the mediators (e.g., Aβ peptides) instead of the root causes (e.g., pathogens, toxins, and insulin resistance) may be yet another reason for the lack of success to date. Here we have taken a very different approach, evaluating and addressing the many potential contributors to cognitive decline for each patient. This has led to unprecedented improvements in cognition. Most importantly, the improvement is typically sustained unless the protocol is discontinued, and even the initial patients treated in 2012 have demonstrated sustained improvement. This effect implies that the root cause(s) of the degenerative process are being targeted, and thus the process itself is impacted, rather than circumventing the process with a monotherapeutic that does not affect the pathophysiology. Therefore, the sustained effect of the protocol represents a major advantage over monotherapeutics. The current study expands on results reported earlier for 19 patients [1,2], here describing 100 patients with cognitive decline and documented improvement. Most of these patients were shown to have Alzheimer’s disease or a pre-Alzheimer’s condition, MCI or SCI; the remainder may or may not have had Alzheimer’s disease, since the evaluations in those cases did not provide definitive evidence of Alzheimer’s, nor did they provide definitive evidence of any other specific degenerative condition. The patients shown to improve included some whose laboratory values suggested each of the major subtypes [3,5] Inflammatory, atrophic, glycotoxic (insulin resistant), and toxic suggesting that the efficacy of this general approach is not restricted to a single subtype of Alzheimer’s disease. The results presented here were obtained by multiple physicians at multiple sites, suggesting that the approach should be scalable and practicable for many physicians. These results should also provide background to support randomized, controlled, prospective clinical trials. Gaining approval for such trials may be difficult, however, since they will necessarily be multi-variable and non-uniform (i.e., personalized). Furthermore, it is highly unlikely that the therapeutic response will act as a linear system, and thus the effect of the program as a whole is unlikely to equal the sum of the effects of each component, making the dissection of the protocol components difficult. However, alternative approaches, such as the removal of single components systematically, or the comparison of large numbers of program effects differing by a few components, may offer some insight into the most and least important components (although of course these may vary from patient to patient). In the current set of 100 patients, for those evaluated by MoCA, MMSE, or SLUMS pre- and post-treatment (72 of the 100), there was a mean improvement of 4.9 points, with a standard deviation of 2.6 and a range of 1-12. Since the natural history is one of decline, the improvements that were documented must be considered as additional to the prevention of decline that would otherwise have occurred. Of course these numbers must be tempered with any failures that occur, so that it will be important to revise these in the context of a randomized, controlled clinical trial. One of the benefits of the protocol used here is that it may enhance pharmaceutical testing and clinical trials: given the lack of improvement in the vast majority of monotherapeutic trials to date, it is possible that one problem results from a floor effect, i.e., there may be a threshold effect needed to measure improvement. However, the positive effects described here might conceivably place the patients in a dynamic range in many cases, such that smaller effects both positive and negative might be detectable. As more patients are treated with this approach, patterns of improvement vs. lack of improvement, timing, which domains typically improve and which do not, and related insights are likely to emerge. Although this was not a focus of the cases reported here, certain observations were made repeatedly. One of these was that the significant others of the patients typically reported that the patients were “more engaged” and more responsive with treatment. Facial recognition, navigation, and memory were often improved, whereas calculation and aphasia were less often improved. For those in whom specific pathogens or toxins were identified, either improvement did not occur until those were targeted therapeutically, or further improvement occurred when they were targeted. Not surprisingly, those patients showing less decline at the time of initiation of treatment responded more readily and completely than those who were further along in the course of the illness. However, there were examples of improvement even with MoCA scores as low as zero. In summary, a targeted, personalized, precision medicine approach that addresses the multiple potential contributors to cognitive decline for each patient shows promise for the treatment of Alzheimer’s disease and its harbingers, MCI and SCI. The improvements documented in the 100 patients reported here provide support for the performance of a prospective, randomized, controlled clinical trial, especially given the current lack of effective treatment for this common and otherwise terminal illness.

Acknowledgments

We are grateful to the many practitioners evaluating and treating patients with cognitive decline, using this comprehensive protocol. We are especially grateful to Dr. Mary Kay Ross, Hilary Shafto, and Margaret Conger for seeing some of the patients reported here, to Dr. Kristine Lokken, Dr. Jonathan Canick, and Dr. Katayoon Shahrokh Walters for some of the neuropsychological evaluations, to Amanda Williams and Cytoplan Ltd. for providing some of the supplements for some patients, to James and Phyllis Easton for critical research support, and to the Evanthea Foundation for support in preparation of a clinical trial.

References